Some biotech stories read like quiet lab notes. Then there’s Affinia Therapeutics, a company writing its science in bold. Based out of Waltham, MA, Affinia isn’t chasing the next big thing in gene therapy; they’re building it from the molecular ground up. The company just locked in a $40M Series C led by New Enterprise Associates (NEA), with fresh energy from Eli Lilly & Co. and returning believers like Atlas Venture, F-Prime Capital, GV, Alexandria Venture Investments, Avidity Partners, Mass General Brigham Ventures, and Perceptive Advisors. This round brings total funding to $210M, stacking even more fuel behind a team that’s already redefined how we think about AAV design.
Let’s be real, gene therapy’s promise has always been tangled up in delivery problems. Most vectors were like blunt instruments trying to perform surgery. Affinia’s answer? The Affinia Rationally-designed Therapies (ART) platform, a generative AI and structural bioinformatics engine that fine-tunes AAV capsids with surgical precision. Think of it as evolution on fast-forward: cardiotropic and myotropic capsids that know exactly where to go, liver-detargeted for safety, optimized through molecular modeling that would make a NASA engineer blush. This is where code meets cell biology, and the result is more than therapy, it’s architecture for the future of medicine.
Founded in 2020 by Luk Vandenberghe, Ph.D., Botond Roska, M.D., Ph.D., Aaron Tward, M.D., Ph.D., and Eric Zinn, Ph.D., the company was built on academic brilliance and commercial instinct. CEO Rick Modi, known for scaling AveXis before its $8.7B exit to Novartis, knows exactly what it takes to turn groundbreaking science into tangible clinical reality. With leadership spanning Harvard, UCSF, ETH Zurich, and Stanford, this team isn’t guessing their way through biology, they’re designing it.
The immediate mission: bring AFTX-201, a gene therapy for BAG3 dilated cardiomyopathy, to the clinic. IND-enabling studies are wrapping, IND submission lands Q4 ’25, and the Phase 1/2 UPBEAT trial kicks off early ’26. Early data in animal models already showed restored cardiac function at lower doses than conventional capsids. That’s not incremental progress, that’s a potential paradigm shift for over 70K patients across the U.S., EU & U.K., where 25% still march toward transplant despite standard care.
The Series C will push AFTX-201 through the clinic while fueling neurological programs next in line. Manufacturing scale-up is covered through Forge Biologics in Indiana, and the team’s expanding clinical, regulatory & production muscle to match their ambition.
So yeah, Affinia Therapeutics isn’t just designing vectors. They’re designing velocity. And with NEA and Lilly now riding shotgun, this story’s about to move from preclinical promise to clinical proof.
